2021-07-21| Trials & Approvals

Cytokinetics Poised to Begin Phase 3 after its HCM Drug Registers Encouraging Data

by Isha Kapoor
Share To

South Francisco, California-based Cytokinetics, Inc. has created an uproar again by announcing positive study findings for an investigational heart drug, CK-274, for treating a chronic cardiovascular disease, Hypertrophic Cardiomyopathy (HCM).

Despite suffering setbacks with its Astellas and Amgen partnerships over the disappointment of its muscle disease drug, reldesemtiv, and heart failure pill, omecamtiv mecarbil (OM), respectively, Cytokinetics is making steady progress. The company is advancing OM to NDA submission following positive Phase 3 results and plans to begin a Phase 3 trial of reldesemtiv based on compelling Phase 2 data.

In addition, the latest promising results from the REDWOOD-HCM trial for a new heart disease candidate, CK-274, have once again brought excitement. The news led Cytokinetics’ stocks to outperform in the market, surging nearly 50% on July 19th.


CK-274 – A Small Molecule Cardiac Myosin Inhibitor

HCM affects an estimated 600,000 to 1.5 million Americans. Currently, there are no FDA-approved medical treatments that directly target hypercontractility underlying HCM.

Cytokinetics, Inc, focuses on developing first-in-class muscle activators and next-gen muscle inhibitors for debilitating cardiovascular or neuromuscular disorders. Its CK-274 is a novel, oral, small molecule cardiac myosin inhibitor.

It is uniquely designed to inhibit hypercontractility associated with HCM by reducing the number of active actin-myosin cross-bridges during each cardiac cycle. In preclinical models, CK-274 reduces myocardial contractility by binding directly to cardiac myosin at a distinct and selective allosteric binding site, thereby preventing myosin from entering a force producing state.

HCM is most often caused by an abnormality in genes in heart muscle, especially the ventricles (left ventricle), or lower heart chambers to contract harder and become thicker or enlarge (hypertrophy) than normal. As a result, the thickened walls become narrow and stiff resulting in blockage or reduction of blood flow to the muscles and organs from the left ventricle. Stiffness in the left ventricle also causes pressure to increase inside the heart resulting in debilitating conditions such as sudden cardiac arrest, atrial fibrillation, stroke, or heart failure.


Positive Phase 2 Data

The topline data from Phase 2 REDWOOD-HCM trial showed statistically significant reductions from baseline compared to placebo in left ventricular outflow tract gradients (LVOT-G) and average post-Valsalva LVOT-G in patients within two weeks of a 10 weeks-dosing schedule of 3 escalating doses of CK-274.

LVOT-G is a measure of blood flow obstruction from the left ventricle. Of note, the reduction in LVOT-G was dose-dependent and sustained through the 10-weeks dosing regimen.

The majority of patients treated with CK-274 (78.6% in Cohort 1 and 92.9% in Cohort 2) achieved the target goal of treatment defined as resting gradient <30 mmHg and post-Valsalva gradient <50 mmHg after 10 weeks compared to placebo.

Cytokinetics said the drug was “well-tolerated” with no “treatment-related serious adverse events” leading to “no interruptions or discontinuation of treatment with CK-274”.

The trial was set up to “see how these results may translate into a clinically meaningful impact on patients’ symptoms and exercise tolerance in Phase 3”, said Marty Maron, M.D. of Tufts University School of Medicine, who is also the principal investigator of the study.


Rivalry with MyoKardia’s Potential Blockbuster 

Cytokinetics has a strong portfolio of muscle activators and inhibitors, but it will face tough competition from mavacamten, a potential blockbuster candidate of BMS’s $13.1 billion acquisition, MyoKardia. Albeit the rivalry, Cytokinetics seemingly holds the edge as the high dose of CK-274 hit its target in nearly 93% of patients as opposed to only 74% treated with MyoKardia’s drug. Further, CK-274 reaches its maximum benefit by six weeks in contrast to less than 18 weeks for mavacamten.

Related Article: Verve Makes Successful Wall Street Debut on Back of its Promising Base Editor


© All rights reserved. Collaborate with us:
Related Post
JPM 2024: More Noteworthy Industry Stories and Updates of Long-rumored Cytokinetics Acquisition
Praxis Stock Hits All-Time Low After Phase 2 Tremor Data Released
‘Heart Attack on a Chip’ Sheds Light on Personalized Drugs Trials
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
Join Us for the SABPA OC/LA 16th Annual Biomedical Forum!
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top